Engineering combination nanomedicines to overcome cancer resistance

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Combination nanomedicine utilizes nanosystems for coordinated delivery of multiple agents, addressing tumor heterogeneity and resistance.
• Clinical translation of nanomedicine faces hurdles including poor pharmacokinetics, inadequate predictive models, and manufacturing limitations.

Purpose of the Study:

• To review design principles of co-delivery nanomedicine platforms for cancer therapy.
• To summarize strategies for integrating diverse therapeutic modalities within nanocarriers.
• To discuss translational challenges and future directions for combination nanomedicine.

Main Methods:

• Examination of design principles for liposomal, polymeric, inorganic, hybrid, and biomimetic nanocarriers.
• Analysis of strategies for combining chemotherapy, immunotherapy, gene/RNA therapies, and physical modalities.
• Review of stimuli-responsive and actively targeted systems for enhanced tumor delivery.

Main Results:

• Co-delivery platforms are evaluated based on pharmacokinetics, biodistribution, endosomal escape, and tumor microenvironment interactions.
• Synergistic therapeutic effects are achieved by integrating multiple treatment modalities.
• Stimuli-responsive and targeted systems demonstrate potential for precise drug release and tumor accumulation.

Conclusions:

• Combination nanomedicine holds significant promise for enhancing cancer therapy efficacy and safety.
• Future efforts must focus on modular, scalable platforms, standardized characterization, and clinically relevant models.
• Addressing manufacturing, quality control, and regulatory pathways is crucial for successful clinical translation.